Efficacy and safety with aumolertinib plus anlotinib for untreated EGFR-mutant NSCLC with brain metastases
Authors:
Open Access
- 1 December 2025
- journal article
- research article
- Published by Springer Nature in npj Precision Oncology
- Vol. 10 (1)
Abstract
The efficacy and prognosis of epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC) patients with brain metastases (BMs) are poor. The third-generation EGFR-tyrosine kinase inhibitor proved to have better intracranial efficacy, which combined with anti-angiogenic drugs can further improve the efficacy. We conducted a single-arm, phase 2 clinical study (GASTO-1063) to explore the intracranial efficacy of aumolertinib plus anlotinib for NSCLC with BMs, with 87 patients enrolled. Median intracranial progression-free survival (PFS) was 30.2 months, median overall PFS was 22.5 months, and median overall survival was not reached. The intracranial objective response rate and intracranial disease control rate were 71.3% and 93.1%. Patients with exon 19 deletion or wild-type TP53 exhibited significantly longer intracranial PFS and PFS compared to those with exon 21 L858R mutation or mutated TP53. Aumolertinib plus anlotinib was effective and well-tolerated as first-line therapy in EGFR-mutant NSCLC patients with BMs. Trial Registration: ClinicalTrials.gov(identifier NCT04978753, registered July 20, 2021).Keywords
Funding Information
- National Natural Science Foundation of China (82472927)
This publication has 44 references indexed in Scilit:
- FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R MutationClinical Lung Cancer, 2024
- Central nervous system metastases in advanced non-small cell lung cancer: A review of the therapeutic landscapeCancer Treatment Reviews, 2024
- Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)Cancer Communications, 2024
- LBA71 A multi-centre open-label randomized phase II study of osimertinib with and without ramucirumab in TKI-naïve EGFR-mutant metastatic NSCLC (RAMOSE trial interim analysis)Annals of Oncology, 2023
- Anti-angiogenesis revisited: reshaping the treatment landscape of advanced non-small cell lung cancerArchives of Pharmacal Research, 2022
- Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 studyCancer Cell, 2021
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018
- First-Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain MetastasesJournal of Thoracic Oncology, 2016
- Mechanisms of resistance to EGFR tyrosine kinase inhibitorsActa Pharmaceutica Sinica B, 2015
- Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signalsCancer Letters, 2008